Imidazoline binding sites and signal transduction pathways.
1. Discrete, non-adrenergic binding sites for imidazolines have been characterized in the brain and periphery. The I1 clonidine-preferring site is mainly distributed in the brain and brain stem, while the I2 idazoxan-preferring site is more widely distributed. 2. The I1 site appears to be associated with modulation of blood pressure. Imidazolines act within the rostral ventrolateral medulla to produce hypotension. The underlying signal transduction mechanism is poorly understood. 3. The imidazolines clonidine and cirazoline inhibited nicotine-stimulated calcium entry into rat phaeochromocytoma (PC-12) cells by a non-adrenergic mechanism. This effect was not attributable to the stimulation of protein kinases. 4. Similarly, clonidine and cirazoline inhibited nicotine-stimulated inward currents into PC-12 cells. This inhibitory action was not altered by inhibitors of signal transducing G-proteins. 5. Clonidine and cirazoline displaced the ion channel ligand [3H]-phencyclidine from nicotinic acetylcholine receptors, suggesting that these drugs act by direct blockade of the intrinsic ion channel of the nicotinic acetylcholine receptor. 6. This ion channel-blocking activity represents a novel action of these imidazolines and may underlie some of the proposed physiological actions of I1 sites.
Prince Henry's Institute of Medical Research, Clayton, Victoria, Australia.
I F
IF
Musgrave
D
D
Krautwurst
G
G
Schultz
D000818:Animals; D001665:Binding Sites; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D006801:Humans; D007093:Imidazoles / Q000378:metabolism* / Q000494:pharmacology*; D054755:Imidazoline Receptors; D011955:Receptors, Drug / Q000145:classification / Q000378:metabolism / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*
D007093:Imidazoles; D054755:Imidazoline Receptors; D011955:Receptors, Drug